Of note, DPP4 inhibitors that lower DPP4 activity have widely been used to improve post‐prandial insulin levels in T2D patients and beneficial effects on clinical outcome was reported by some studies on COVID‐19 patients with T2D that continued DPP4 inhibitor regimen.86, 87. This evidence concerns the gene DPP4 and COVID-19.